Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme.
Ulcerative colitis
safety
tofacitinib
Journal
Journal of Crohn's & colitis
ISSN: 1876-4479
Titre abrégé: J Crohns Colitis
Pays: England
ID NLM: 101318676
Informations de publication
Date de publication:
03 Apr 2023
03 Apr 2023
Historique:
medline:
5
4
2023
pubmed:
21
9
2022
entrez:
20
9
2022
Statut:
ppublish
Résumé
Tofacitinib is an oral small molecule Janus kinase [JAK] inhibitor for the treatment of ulcerative colitis. We report an integrated summary of tofacitinib safety [exposure: ≤7.8 years] from the global clinical programme. Patients receiving tofacitinib 5 or 10 mg twice daily [BID] from completed phase [P]2/3 placebo-controlled studies, an open-label, long-term extension study [final data cut-off: August 24, 2020], and interim analysis of a P3b/4 study (interim data cut-off: February 20, 2020; Overall plus P3b/4 [2020] Cohort) were included. Proportions with adverse events [AEs] and serious AEs, and incidence rates [IRs; unique patients with events/100 patient-years] for deaths and AEs of special interest [AESI] were evaluated. Opportunistic infections, malignancies, major adverse cardiovascular events [MACE] and gastrointestinal perforations were adjudicated. In total, 1157 patients received one or more dose of tofacitinib (mean duration: 946.9 days); 955/1157 [83%] received a predominant dose of 10 mg BID; 412/1157 [35.6%] received tofacitinib for >4 years; 992/1157 [85.7%] had AEs, 244/1157 [21.1%] had serious AEs and 134/1157 (11.6%) discontinued use due to AEs. IRs [95% confidence intervals] for all tofacitinib doses were: deaths, 0.23 [0.09-0.46]; serious infections, 1.69 [1.26-2.21]; herpes zoster [non-serious and serious], 3.30 [2.67-4.04]; opportunistic infections, 1.03 [0.70-1.46]; malignancies (excluding non-melanoma skin cancer [NMSC]), 0.84 [0.55-1.24]; NMSC, 0.73 [0.45-1.10]; MACE, 0.29 [0.13-0.55]; deep vein thrombosis, 0.03 [0.00-0.18]; pulmonary embolism, 0.19 [0.07-0.42]; gastrointestinal perforations, 0.10 [0.02-0.28]. AESI IRs were stable to 7.8 years and generally <2.0 in the Overall plus P3b/4 [2020] Cohort, with the exception of herpes zoster [a known risk of tofacitinib treatment]. ClinicalTrials.gov:NCT00787202;NCT01465763;NCT01458951;NCT01458574;NCT01470612;NCT03281304JCC Topic/keyword selection: 3. Clinical trials.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Tofacitinib is an oral small molecule Janus kinase [JAK] inhibitor for the treatment of ulcerative colitis. We report an integrated summary of tofacitinib safety [exposure: ≤7.8 years] from the global clinical programme.
METHODS
METHODS
Patients receiving tofacitinib 5 or 10 mg twice daily [BID] from completed phase [P]2/3 placebo-controlled studies, an open-label, long-term extension study [final data cut-off: August 24, 2020], and interim analysis of a P3b/4 study (interim data cut-off: February 20, 2020; Overall plus P3b/4 [2020] Cohort) were included. Proportions with adverse events [AEs] and serious AEs, and incidence rates [IRs; unique patients with events/100 patient-years] for deaths and AEs of special interest [AESI] were evaluated. Opportunistic infections, malignancies, major adverse cardiovascular events [MACE] and gastrointestinal perforations were adjudicated.
RESULTS
RESULTS
In total, 1157 patients received one or more dose of tofacitinib (mean duration: 946.9 days); 955/1157 [83%] received a predominant dose of 10 mg BID; 412/1157 [35.6%] received tofacitinib for >4 years; 992/1157 [85.7%] had AEs, 244/1157 [21.1%] had serious AEs and 134/1157 (11.6%) discontinued use due to AEs. IRs [95% confidence intervals] for all tofacitinib doses were: deaths, 0.23 [0.09-0.46]; serious infections, 1.69 [1.26-2.21]; herpes zoster [non-serious and serious], 3.30 [2.67-4.04]; opportunistic infections, 1.03 [0.70-1.46]; malignancies (excluding non-melanoma skin cancer [NMSC]), 0.84 [0.55-1.24]; NMSC, 0.73 [0.45-1.10]; MACE, 0.29 [0.13-0.55]; deep vein thrombosis, 0.03 [0.00-0.18]; pulmonary embolism, 0.19 [0.07-0.42]; gastrointestinal perforations, 0.10 [0.02-0.28].
CONCLUSIONS
CONCLUSIONS
AESI IRs were stable to 7.8 years and generally <2.0 in the Overall plus P3b/4 [2020] Cohort, with the exception of herpes zoster [a known risk of tofacitinib treatment]. ClinicalTrials.gov:NCT00787202;NCT01465763;NCT01458951;NCT01458574;NCT01470612;NCT03281304JCC Topic/keyword selection: 3. Clinical trials.
Identifiants
pubmed: 36124702
pii: 6702643
doi: 10.1093/ecco-jcc/jjac141
pmc: PMC10069618
doi:
Substances chimiques
Janus Kinase Inhibitors
0
Protein Kinase Inhibitors
0
Pyrroles
0
tofacitinib
87LA6FU830
Banques de données
ClinicalTrials.gov
['NCT01458574', 'NCT03281304', 'NCT00787202', 'NCT01465763', 'NCT01470612', 'NCT01458951']
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
338-351Subventions
Organisme : Pfizer
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation.
Références
MMWR Morb Mortal Wkly Rep. 2018 Jan 26;67(3):103-108
pubmed: 29370152
Clin Gastroenterol Hepatol. 2020 Jan;18(1):123-132.e3
pubmed: 31077827
N Engl J Med. 2022 Jan 27;386(4):316-326
pubmed: 35081280
Circulation. 2014 Apr 8;129(14):1502-9
pubmed: 24508826
Inflamm Bowel Dis. 2018 Jul 12;24(8):1791-1800
pubmed: 29726897
Aliment Pharmacol Ther. 2022 Feb;55(4):464-478
pubmed: 34854095
Ann Rheum Dis. 2016 Oct;75(10):1843-7
pubmed: 27113415
Int J Obes (Lond). 2013 Mar;37(3):333-40
pubmed: 22546772
Gastroenterol Res Pract. 2019 Jan 13;2019:3012509
pubmed: 30733802
Inflamm Bowel Dis. 2021 Aug 19;27(9):1394-1408
pubmed: 33324993
Aliment Pharmacol Ther. 2019 Nov;50(10):1068-1076
pubmed: 31599001
Thromb Haemost. 2001 Mar;85(3):430-4
pubmed: 11307809
Aliment Pharmacol Ther. 2015 Jun;41(11):1141-8
pubmed: 25864945
Gut. 2011 Jul;60(7):937-43
pubmed: 21339206
Therap Adv Gastroenterol. 2021 Dec 23;14:17562848211064004
pubmed: 34987608
Inflamm Bowel Dis. 2018 Sep 15;24(10):2258-2265
pubmed: 29850873
Drug Saf. 2021 May;44(5):515-530
pubmed: 33527177
N Engl J Med. 2017 May 4;376(18):1723-1736
pubmed: 28467869
Inflamm Bowel Dis. 2023 Jan 5;29(1):85-96
pubmed: 35648151
Aliment Pharmacol Ther. 2022 Feb;55(3):302-310
pubmed: 34626429
Gastroenterology. 2011 Nov;141(5):1621-28.e1-5
pubmed: 21708105
Digestion. 2020;101 Suppl 1:136-145
pubmed: 32799195
Aliment Pharmacol Ther. 2021 Aug;54(4):429-440
pubmed: 34165201
Ann Rheum Dis. 2020 Nov;79(11):1400-1413
pubmed: 32759265
Gastroenterology. 2020 May;158(6):1554-1573.e12
pubmed: 31926171
BMJ Open Gastroenterol. 2021 Feb;8(1):
pubmed: 33597152
Clin Gastroenterol Hepatol. 2019 Jul;17(8):1541-1550
pubmed: 30476584
J Crohns Colitis. 2014 Jun;8(6):443-68
pubmed: 24613021
Intern Emerg Med. 2007 Oct;2(3):210-8
pubmed: 17909702
J Crohns Colitis. 2021 Jul 5;15(7):1130-1141
pubmed: 33290538
Nat Rev Rheumatol. 2017 May;13(5):320
pubmed: 28360424
J Natl Cancer Inst. 2008 Sep 3;100(17):1215-22
pubmed: 18728282
Inflamm Bowel Dis. 2022 Feb 1;28(2):234-245
pubmed: 33742652
Clin Transl Gastroenterol. 2021 Jul 6;12(7):e00380
pubmed: 34228004
World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253
pubmed: 11234459
Dig Dis. 2015;33(1):52-7
pubmed: 25531497
N Engl J Med. 2012 Aug 16;367(7):616-24
pubmed: 22894574